Why Google Wants to Map Your Body With Its Baseline Study

Google recently announced that it will collect genetic information from thousands of people to “map out” the healthy human body. Here’s what you need to know about the Google Baseline Study.

Aug 31, 2014 at 12:02PM

Google (NASDAQ:GOOG) (NASDAQ:GOOGL) is a company built on providing information to make our lives easier. While that information included search histories, maps, and cloud-based software in the past, the search giant recently launched a new Google X project to better understand the human body.

The project, known as the Baseline Study, will organize data from accumulated genetic profiles. Google will initially collect genetic data from 175 people, followed by thousands more. Dr. Andrew Conrad -- a molecular biologist known for developing cheap HIV tests for blood donations -- will lead a team of 70-100 medical experts to accomplish the study.


Source: Pixabay.

Baseline will map out participants' entire genomes, their parents' genetic history, fluctuating heart rates, metabolism, and even how chemical reactions change their genetic behavior. The ultimate goal is to identify genetic biomarkers for the early detection of major health issues such as high cholesterol, heart disease, and cancer. This information could possibly be made available to medical companies researching new gene-targeted treatments.

Major concerns, massive growth potential
While Baseline sounds impressive, it also raises privacy and regulatory concerns if the program is expanded to include more genetic profiles.

The long-term implications of a searchable database of mapped genomes are alarming, considering that Google is the largest search engine in the world. However, Google has promised that the results will remain anonymous and limited to medical purposes.

But even if Baseline wins over privacy advocates, the U.S. government will definitely be concerned about Google amassing a database of genetic records. The privacy requirements of HIPAA will cause huge problems if Google ever wants to mine that data in any commercial way -- a fact that CEO Larry Page mentioned during an interview at the Khosla Ventures CEO Summit. Page stated that he worried about missing out on "really great possibilities that are certainly on the data-mining end" in healthcare.

Plunging testing costs and faster machines would definitely help accelerate Baseline's progress. In January, life sciences company Illumina (NASDAQ:ILMN) broke the "genome sound barrier" with a machine which could sequence the entire human genome for just $1,000. Less than a decade ago, that process would have cost $250,000.


Illumina's $1,000 per sequence system, the HiSeq X Ten. Source: Illumina.

Google's not alone
Google isn't the only tech company investing in genome sequencing. In January, Sony (NYSE:SNE) announced a partnership with Japanese medical portal M3 and Illumina to launch a genome information company known as P5.

While Baseline asks for volunteers to enter their genetic information into Google's system, P5 aims to provide genome analysis services for research institutions and other businesses across Japan. The ultimate goal is to help businesses develop better personalized medicine and healthcare services. 

Mass genomics projects existed long before Google's Baseline Study and P5, but those studies were mostly conducted within universities and private institutions, not publicly traded companies.

Another piece of Google's healthcare puzzle
Google's Baseline Study isn't the company's first foray into the global healthcare industry.

Google tried to create a united personal health record with Google Health, which was canceled in 2011 due to a lack of industry support and public recognition. Last September, Google established Calico, a biotech subsidiary to study the effects of aging, although not much is known about its current projects. Google announced Google Fit, a centralized system for fitness apps and wearables in June.

Novartis (NYSE:NVS) recently licensed Google's "smart lens" technology for diabetes and eye care. On the horizon is Google Glass, which hasn't gained much public support, but is widely considered a valuable hands-free tool for hospitals.

A Foolish final word
Since HIPAA regulations will prevent Google from mining genetic data for commercial uses, Baseline's data probably won't ever be connected to consumer-facing products like Google Fit, Android devices, or Google Glass.

However, Baseline could be merged with Calico to assist in the development of new treatments, and could also help Google X's Life Sciences Group develop new wearable devices. Baseline's information could also be shared with the biopharmaceutical industry, which would accelerate the development of gene-targeted drugs.

While Baseline might seems like a "moon shot" at first, it really isn't. Baseline fits into Google's strategy of collecting information and organizing it for new uses, and could eventually be as valuable a tool to the healthcare industry as Google Maps is to drivers.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Google (A shares), Google (C shares), and Illumina. The Motley Fool owns shares of Google (A shares) and Google (C shares). Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information